223 related articles for article (PubMed ID: 25421347)
1. Overcoming mantle cell lymphoma's ibrutinib resistance.
Sinha G
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25421347
[No Abstract] [Full Text] [Related]
2. Ibrutinib for mantle cell lymphoma.
Tucker DL; Rule SA
Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
de Rooij MF; Kuil A; Kater AP; Kersten MJ; Pals ST; Spaargaren M
Blood; 2015 Apr; 125(14):2306-9. PubMed ID: 25838279
[No Abstract] [Full Text] [Related]
4. The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.
Vidal-Crespo A; Rodriguez V; Matas-Cespedes A; Lee E; Rivas-Delgado A; Giné E; Navarro A; Beà S; Campo E; López-Guillermo A; Lopez-Guerra M; Roué G; Colomer D; Pérez-Galán P
Haematologica; 2017 Nov; 102(11):e447-e451. PubMed ID: 28838994
[No Abstract] [Full Text] [Related]
5. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
Jacobson C; Kopp N; Layer JV; Redd RA; Tschuri S; Haebe S; van Bodegom D; Bird L; Christie AL; Christodoulou A; Saur A; Tivey T; Zapf S; Bararia D; Zimber-Strobl U; Rodig SJ; Weigert O; Weinstock DM
Blood; 2016 Nov; 128(21):2517-2526. PubMed ID: 27742706
[TBL] [Abstract][Full Text] [Related]
6. Targeting protein kinase C in mantle cell lymphoma.
Rauert-Wunderlich H; Rudelius M; Ott G; Rosenwald A
Br J Haematol; 2016 May; 173(3):394-403. PubMed ID: 26914495
[TBL] [Abstract][Full Text] [Related]
7. [Ibrutinib prescription in B-cell lymphoid neoplasms].
Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib approved for mantle cell lymphoma.
Cancer Discov; 2014 Jan; 4(1):OF1. PubMed ID: 24402946
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
11. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
12. Targeting of B-cell receptor signalling in B-cell malignancies.
Jerkeman M; Hallek M; Dreyling M; Thieblemont C; Kimby E; Staudt L
J Intern Med; 2017 Nov; 282(5):415-428. PubMed ID: 28295729
[TBL] [Abstract][Full Text] [Related]
13. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.
Zhao X; Bodo J; Sun D; Durkin L; Lin J; Smith MR; Hsi ED
Br J Haematol; 2015 Mar; 168(5):765-8. PubMed ID: 25284608
[No Abstract] [Full Text] [Related]
14. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
Ruella M; Kenderian SS; Shestova O; Fraietta JA; Qayyum S; Zhang Q; Maus MV; Liu X; Nunez-Cruz S; Klichinsky M; Kawalekar OU; Milone M; Lacey SF; Mato A; Schuster SJ; Kalos M; June CH; Gill S; Wasik MA
Clin Cancer Res; 2016 Jun; 22(11):2684-96. PubMed ID: 26819453
[TBL] [Abstract][Full Text] [Related]
15. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
16. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
Ma J; Lu P; Guo A; Cheng S; Zong H; Martin P; Coleman M; Wang YL
Br J Haematol; 2014 Sep; 166(6):849-61. PubMed ID: 24957109
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.
Zhang L; Newberry KJ; Wang M
Expert Rev Clin Immunol; 2013 Jun; 9(6):495-7. PubMed ID: 23730878
[No Abstract] [Full Text] [Related]
18. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.
Mohanty A; Sandoval N; Das M; Pillai R; Chen L; Chen RW; Amin HM; Wang M; Marcucci G; Weisenburger DD; Rosen ST; Pham LV; Ngo VN
Oncotarget; 2016 Nov; 7(45):73558-73572. PubMed ID: 27713153
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
Compagno M; Wang Q; Pighi C; Cheong TC; Meng FL; Poggio T; Yeap LS; Karaca E; Blasco RB; Langellotto F; Ambrogio C; Voena C; Wiestner A; Kasar SN; Brown JR; Sun J; Wu CJ; Gostissa M; Alt FW; Chiarle R
Nature; 2017 Feb; 542(7642):489-493. PubMed ID: 28199309
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib in B lymphoid malignancies.
Smith MR
Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]